166 related articles for article (PubMed ID: 38565886)
21. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K
Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
[TBL] [Abstract][Full Text] [Related]
23. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF
Tabernero J; Grothey A; Arnold D; de Gramont A; Ducreux M; O'Dwyer P; Tahiri A; Gilberg F; Irahara N; Schmoll HJ; Van Cutsem E
ESMO Open; 2022 Oct; 7(5):100559. PubMed ID: 36029653
[TBL] [Abstract][Full Text] [Related]
24. Multicenter phase II clinical study of the efficiency and safety of capecitabine plus intermittent oxaliplatin with bevacizumab as first-line therapy in patients with metastatic colorectal cancer (VOICE trial).
Kosugi C; Koda K; Denda T; Ishibashi K; Ishida H; Seike K; Sakata H; Yanagisawa S; Miyazaki A; Takayama W; Koike N; Shimizu H; Matsubara H
Int J Colorectal Dis; 2021 Dec; 36(12):2637-2647. PubMed ID: 34368890
[TBL] [Abstract][Full Text] [Related]
25. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Saltz LB; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Cassidy J
J Clin Oncol; 2008 Apr; 26(12):2013-9. PubMed ID: 18421054
[TBL] [Abstract][Full Text] [Related]
26. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
27. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
Yamada Y; Denda T; Gamoh M; Iwanaga I; Yuki S; Shimodaira H; Nakamura M; Yamaguchi T; Ohori H; Kobayashi K; Tsuda M; Kobayashi Y; Miyamoto Y; Kotake M; Shimada K; Sato A; Morita S; Takahashi S; Komatsu Y; Ishioka C
Ann Oncol; 2018 Mar; 29(3):624-631. PubMed ID: 29293874
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer.
Munemoto Y; Kanda M; Ishibashi K; Hata T; Kobayashi M; Hasegawa J; Fukunaga M; Takagane A; Otsuji T; Miyake Y; Nagase M; Sakamoto J; Matsuoka M; Oba K; Mishima H
BMC Cancer; 2015 Oct; 15():786. PubMed ID: 26497654
[TBL] [Abstract][Full Text] [Related]
30. Bi-weekly Capecitabine-Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer -The PHOENiX Trial.
Matsui T; Nagata N; Hirata K; Okazaki S; Sato S; Nakamura M; Kim H; Oba K; Sakamoto J; Mishima H
Anticancer Res; 2016 Jul; 36(7):3437-43. PubMed ID: 27354605
[TBL] [Abstract][Full Text] [Related]
31. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Int J Clin Oncol; 2010 Jun; 15(3):256-62. PubMed ID: 20198398
[TBL] [Abstract][Full Text] [Related]
32. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
33. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N
BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305
[TBL] [Abstract][Full Text] [Related]
34. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
Kim Y; Kim TW; Han SW; Ahn JB; Kim ST; Lee J; Park JO; Park YS; Lim HY; Kang WK
Cancer Res Treat; 2019 Jul; 51(3):1128-1134. PubMed ID: 30477287
[TBL] [Abstract][Full Text] [Related]
35. Neoadjuvant therapy of bevacizumab in combination with oxaliplatin and capecitabine (XELOX) for patients with metastatic colorectal cancer with unresectable liver metastases: a phase II, open-label, single-arm, noncomparative trial.
Chen HH; Lin JK; Chen JB; Chuang CH; Liu MC; Wang JY; Changchien CR
Asia Pac J Clin Oncol; 2018 Feb; 14(1):61-68. PubMed ID: 28906589
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine plus oxaliplatin (xelox) in the treatment of chemotherapy-naive patients with metastatic colorectal cancer.
Yaman E; Uner A; Er O; Coskun U; Buyukberber S; Dikilitas M; Polat M; Yamac D; Kaya AO; Yildiz R; Ozturk B; Benekli M
Med Oncol; 2007; 24(4):431-5. PubMed ID: 17917094
[TBL] [Abstract][Full Text] [Related]
37. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial.
Lenz HJ; Parikh A; Spigel DR; Cohn AL; Yoshino T; Kochenderfer M; Elez E; Shao SH; Deming D; Holdridge R; Larson T; Chen E; Mahipal A; Ucar A; Cullen D; Baskin-Bey E; Kang T; Hammell AB; Yao J; Tabernero J
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485190
[TBL] [Abstract][Full Text] [Related]
38. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab.
Kotaka M; Xu R; Muro K; Park YS; Morita S; Iwasa S; Uetake H; Nishina T; Nozawa H; Matsumoto H; Yamazaki K; Han SW; Wang W; Ahn JB; Deng Y; Cho SH; Ba Y; Lee KW; Zhang T; Satoh T; Buyse ME; Ryoo BY; Shen L; Sakamoto J; Kim TW
Chin J Cancer; 2016 Dec; 35(1):102. PubMed ID: 28007025
[TBL] [Abstract][Full Text] [Related]
39. Capecitabine Plus Oxaliplatin and Bevacizumab, Followed by Maintenance Treatment With Capecitabine and Bevacizumab for Patients Aged > 75 Years With Metastatic Colorectal Cancer.
Petrioli R; Francini E; Cherri S; Torre P; Fiaschi AI; Miano ST; Marrelli D; Rovello F; Francini G
Clin Colorectal Cancer; 2018 Dec; 17(4):e663-e669. PubMed ID: 30153975
[TBL] [Abstract][Full Text] [Related]
40. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
Rothenberg ML; Cox JV; Butts C; Navarro M; Bang YJ; Goel R; Gollins S; Siu LL; Laguerre S; Cunningham D
Ann Oncol; 2008 Oct; 19(10):1720-6. PubMed ID: 18550577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
